IP Library › Granted Patent US 12678438
Granted Patent B2
US 12678438 · App. 17/605,971 · Granted Jul 14, 2026

Treatment of cancer with CDK inhibitors

Inventor: Irfan Asangani (Wallingford, PA)
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
A61K31/506A61K31/4164A61P35/00C12Q1/6886C12Q2600/106C12Q2600/118C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12678438
App. No.
17/605,971
Granted
Jul 14, 2026
Kind
B2
Abstract

The present invention relates to methods of treating cancer by administration of a cyclin dependent kinase (CDK) inhibitor to a subject.

Claims (7)

1 . A method for treating an androgen receptor (AR)-dependent cancer, comprising administering an effective amount of an inhibitor of cyclin dependent kinase 7 (CDK7) or a corresponding pharmaceutical composition to a human subject in need thereof, wherein the (AR)-dependent cancer is prostate cancer.

2 . The method for treating an AR-dependent cancer according to claim 1 , wherein the prostate cancer is castration resistant prostate cancer (CRPC).

3 . The method for treating an AR-dependent cancer according to claim 1 , wherein the CDK7 inhibitor is THZ1, SY-5609, CT7001, seliciclib, TG-02, PHA-793887, SY-351, roniciclib, SNS-032, BS-181L, and BS-194.

4 . The method for treating an AR-dependent cancer according to claim 1 , wherein the subject is resistant to anti-androgen therapy.

5 . The method for treating an AR-dependent cancer according to claim 4 , wherein the anti-androgen therapy comprises abiraterone enzalutamide, apalutamide, or darolutamide.

6 . The method for treating an AR-dependent cancer according to claim 1 , wherein the administering the cyclin dependent kinase 7 (CDK7) inhibitor or a pharmaceutical composition thereof, results in one or more a reduction in tumor volume, a loss of PSA expression, increased necrosis, reduced proliferative activity, increased apoptosis, a reduction in p-MED1 levels in a tumor, reduced plasma PSA expression.

7 . The method for treating an AR-dependent cancer according to claim 1 , wherein the composition is formulated for oral administration or is formulated for intravenous injection.